Close Menu

Interpace Diagnostics

The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.

The company said in a filing with the US Securities and Exchange Commission that it is not in compliance with the exchange's minimum shareholders' equity requirement.

Contributing to the revenue increase was a rise in in test and collection volume for its thyroid cancer diagnostics.

The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

Pages